文献速递乳腺癌

细胞周期蛋白E1表达与帕博西利在既往治疗过的激素受体阳性转移性乳腺癌中的疗效

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
PubMed 文献 · J Clin Oncol · 2019-02-26

PALOMA-3试验将521例内分泌治疗后的转移性乳腺癌患者随机分配至帕博西利联合氟维司群组或安慰剂联合氟维司群组,对302例患者肿瘤组织进行基因表达分析。高CCNE1 mRNA表达与帕博西利联合氟维司群组中位无进展生存期缩短相关(高表达7.6个月 vs 低表达14.1个月),交互作用P=0.00238(FDR校正后P=0.0238)。结论认为帕博西利联合氟维司群在所有生物标志物组中均显示疗效,但高CCNE1 mRNA表达与相对耐药相关。

要点

  • 高CCNE1 mRNA表达患者接受帕博西利联合氟维司群的中位PFS为7.6个月,低表达为14.1个月。
  • 交互作用P=0.00238(FDR校正后P=0.0238),提示CCNE1表达与帕博西利疗效存在交互作用。
  • CDK4、CDK6、细胞周期蛋白D1和RB1表达与治疗之间未发现显著交互作用。

核心结论

  • 帕博西利联合氟维司群在所有生物标志物组中均显示疗效,但高CCNE1 mRNA表达与相对耐药相关。

研究设计与样本

  • PALOMA-3试验(NCT01942135)随机分配521例内分泌治疗后的转移性乳腺癌患者接受帕博西利联合氟维司群或安慰剂联合氟维司群。
  • 对302例患者肿瘤组织进行基因表达分析(帕博西利组194例,安慰剂组108例)。
  • 独立验证队列来自POP临床试验(NCT02008734),61例原发乳腺癌患者接受2周帕博西利治疗。

主要发现

  • 高CCNE1 mRNA表达患者中位PFS:帕博西利组7.6个月 vs 安慰剂组4.0个月;低CCNE1 mRNA表达患者中位PFS:帕博西利组14.1个月 vs 安慰剂组4.8个月。
  • 交互作用P未校正=0.00238;FDR校正后P=0.0238。
  • CCNE1 mRNA在转移灶活检组织中的预测价值高于档案原发活检组织。
  • CDK4、CDK6、细胞周期蛋白D1和RB1表达水平与治疗之间未发现显著交互作用。
  • 帕博西利在luminal A和luminal B肿瘤中均有效。

关键数值与推荐

  • 高CCNE1 mRNA表达患者中位PFS:帕博西利组7.6个月 vs 安慰剂组4.0个月。
  • 低CCNE1 mRNA表达患者中位PFS:帕博西利组14.1个月 vs 安慰剂组4.8个月。
  • 交互作用P未校正=0.00238;FDR校正后P=0.0238。
  • POP试验中高CCNE1 mRNA表达与帕博西利抗增殖活性较差相关(P=0.005)。

临床怎么用

  • 帕博西利联合氟维司群在所有生物标志物组中均显示疗效。
  • 高CCNE1 mRNA表达与帕博西利相对耐药相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to fulvestrant. METHODS: The PALOMA-3 ( ClinicalTrials.gov identifier: NCT01942135) trial randomly assigned 521 endocrine-pretreated patients with metastatic breast cancer to receive palbociclib plus fulvestrant or placebo plus fulvestrant. Primary analysis was first conducted on 10 genes on the basis of pathway biology and evidence from previous studies followed by a systematic panel-wide search among 2,534 cancer-related genes. The association of gene expression with the effect of palbociclib on progression-free survival (PFS) was evaluated using Cox proportional hazards regression analysis, with gene expression as a continuous variable or dichotomized by median. An independent breast cancer cohort from the Preoperative Palbociclib (POP) Clinical Trial ( ClinicalTrials.gov identifier: NCT02008734) was used for validation, in 61 patients with primary breast cancer treated with 2 weeks of palbociclib. RESULTS: In the PALOMA-3 trial, 302 patients had tumor tissue analyzed (palbociclib arm, 194 patients; placebo arm, 108 patients). Palbociclib efficacy was lower in patients with high versus low cyclin E1 (CCNE1) mRNA expression (median PFS: palbociclib arm, 7.6 v 14.1 months; placebo arm, 4.0 v 4.8 months, respectively; interaction P unadjusted = .00238; false discovery rate-adjusted P = .0238). CCNE1 mRNA was more predictive in metastatic than in archival primary biopsy tissue samples. No significant interaction was found between treatment and expression levels of CDK4, CDK6, cyclin D1, and RB1. Palbociclib was efficacious in both luminal A and luminal B tumors. High CCNE1 mRNA expression was associated with poor antiproliferative activity of palbociclib in the POP trial (P = .005). CONCLUSION: Addition of palbociclib to fulvestrant demonstrated efficacy in all biomarker groups, although high CCNE1 mRNA expression was associated with relative resistance to palbociclib.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Turner NC, Liu Y, Zhu Z, et al. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. J Clin Oncol. 2019. PMID: 30807234. doi:10.1200/JCO.18.00925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。